WO1998013059A1 - Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells - Google Patents
Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells Download PDFInfo
- Publication number
- WO1998013059A1 WO1998013059A1 PCT/US1997/017410 US9717410W WO9813059A1 WO 1998013059 A1 WO1998013059 A1 WO 1998013059A1 US 9717410 W US9717410 W US 9717410W WO 9813059 A1 WO9813059 A1 WO 9813059A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- aminobenzyl
- amino
- hydrolyzable
- prodrug
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title claims abstract description 103
- 239000000651 prodrug Substances 0.000 title claims abstract description 103
- 206010061289 metastatic neoplasm Diseases 0.000 title claims abstract description 54
- 230000001394 metastastic effect Effects 0.000 title claims abstract description 53
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 29
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 115
- 102000004225 Cathepsin B Human genes 0.000 claims abstract description 50
- 108090000712 Cathepsin B Proteins 0.000 claims abstract description 50
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 50
- 229940126585 therapeutic drug Drugs 0.000 claims abstract description 41
- 125000006850 spacer group Chemical group 0.000 claims abstract description 35
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims abstract description 26
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 26
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 20
- 239000000758 substrate Substances 0.000 claims abstract description 20
- 229940127093 camptothecin Drugs 0.000 claims abstract description 17
- 229960004857 mitomycin Drugs 0.000 claims abstract description 13
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 11
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims abstract description 8
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims abstract description 8
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 esperamycin Chemical compound 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 31
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 claims description 15
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 claims description 14
- RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 claims description 8
- 108010034892 glycyl-arginyl-glycyl-aspartyl-serine Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000029816 Collagenase Human genes 0.000 claims description 5
- 108060005980 Collagenase Proteins 0.000 claims description 5
- 229960002424 collagenase Drugs 0.000 claims description 5
- YPHBVXSTAIBWLZ-YGOYIFOWSA-N (2S,3R)-2-[benzoyl-[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]oxyamino]-3-hydroxybutanoic acid Chemical compound C([C@@H](C(=O)ON([C@@H]([C@H](O)C)C(O)=O)C(=O)C=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 YPHBVXSTAIBWLZ-YGOYIFOWSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 91
- 210000000170 cell membrane Anatomy 0.000 abstract description 7
- 102000035195 Peptidases Human genes 0.000 abstract description 4
- 108091005804 Peptidases Proteins 0.000 abstract description 4
- 239000004365 Protease Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 132
- 206010028980 Neoplasm Diseases 0.000 description 73
- 238000003786 synthesis reaction Methods 0.000 description 68
- 230000015572 biosynthetic process Effects 0.000 description 67
- 201000011510 cancer Diseases 0.000 description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 239000007787 solid Substances 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 33
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 239000000243 solution Substances 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- 239000000047 product Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 229910001868 water Inorganic materials 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 206010027476 Metastases Diseases 0.000 description 15
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 14
- ZMXDDKWLCZADIW-YYWVXINBSA-N N,N-dimethylformamide-d7 Chemical compound [2H]C(=O)N(C([2H])([2H])[2H])C([2H])([2H])[2H] ZMXDDKWLCZADIW-YYWVXINBSA-N 0.000 description 14
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 230000003248 secreting effect Effects 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 230000002147 killing effect Effects 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- ZEZGJKSEBRELAS-PEDHHIEDSA-N (2s)-1-[(2s,3s)-3-methyl-2-[[(2s,3s)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@H](C(O)=O)CCC1 ZEZGJKSEBRELAS-PEDHHIEDSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000016359 Fibronectins Human genes 0.000 description 10
- 108010067306 Fibronectins Proteins 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 102000007547 Laminin Human genes 0.000 description 8
- 108010085895 Laminin Proteins 0.000 description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- AVXRNUMVGRLMBL-GJZGRUSLSA-N (2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-6-aminohexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)C)CC1=CC=CC=C1 AVXRNUMVGRLMBL-GJZGRUSLSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 150000008575 L-amino acids Chemical class 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 108010030011 N-acetylphenylalanyllysine Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 239000012258 stirred mixture Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 150000008574 D-amino acids Chemical group 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000003712 lysosome Anatomy 0.000 description 5
- 230000001868 lysosomic effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000002001 anti-metastasis Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 229960005215 dichloroacetic acid Drugs 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 3
- CTYHQVFFQRDJSN-LHEWISCISA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[[(4-methoxyphenyl)-diphenylmethyl]amino]hexanoic acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)NCCCC[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 CTYHQVFFQRDJSN-LHEWISCISA-N 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 3
- LBSXSAXOLABXMF-UHFFFAOYSA-N 4-Vinylaniline Chemical compound NC1=CC=C(C=C)C=C1 LBSXSAXOLABXMF-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 3
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 3
- 241000557626 Corvus corax Species 0.000 description 3
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 3
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010064390 Tumour invasion Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 108010013726 glycyl-arginyl-glycyl-glutamyl-serine Proteins 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 125000000405 phenylalanyl group Chemical group 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- NTEDOEBWPRVVSG-FQUUOJAGSA-N (2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-FQUUOJAGSA-N 0.000 description 2
- QSAUHWWUFRQEMX-DEOSSOPVSA-N (2s)-2-amino-6-[[(4-methoxyphenyl)-diphenylmethyl]amino]hexanoic acid Chemical compound C1=CC(OC)=CC=C1C(NCCCC[C@H](N)C(O)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 QSAUHWWUFRQEMX-DEOSSOPVSA-N 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 2
- SEFVRKXJJPMVHQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid Chemical compound NC(N)=NCCCC(NC(=O)CN)C(=O)NCC(=O)NC(CC(O)=O)C(O)=O SEFVRKXJJPMVHQ-UHFFFAOYSA-N 0.000 description 2
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 2
- QXPXILGITKUCLM-UHFFFAOYSA-N 2-benzylidenepropane-1,3-diol Chemical compound OCC(CO)=CC1=CC=CC=C1 QXPXILGITKUCLM-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940123329 Cathepsin B inhibitor Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 229940097265 cysteamine hydrochloride Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 229910017059 organic montmorillonite Inorganic materials 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- FBDOJYYTMIHHDH-OZBJMMHXSA-N (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-2,4,6,8,10,14,20-heptaen-18-one Chemical compound CC[C@@]1(O)C(=O)OCC2=CN3Cc4cc5ccccc5nc4C3C=C12 FBDOJYYTMIHHDH-OZBJMMHXSA-N 0.000 description 1
- FHLXUWOHGKLDNF-UHFFFAOYSA-N (2-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=CC=C1OC(Cl)=O FHLXUWOHGKLDNF-UHFFFAOYSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- XJRPQJYLNDRHQD-JDIVNGTKSA-N (3s)-4-[(2s)-2-[[2-[[(2s)-1-[[(2s,3s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoe Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CS)C1=CC=C(O)C=C1 XJRPQJYLNDRHQD-JDIVNGTKSA-N 0.000 description 1
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 1
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OTFAJNHMHDKAKM-UHFFFAOYSA-N 1-(2-chloro-2,2-diphenylethyl)-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1CC(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 OTFAJNHMHDKAKM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QQDIKWXZOLTRDH-UHFFFAOYSA-N 2-[(4-nitrophenyl)methylidene]propane-1,3-diol Chemical compound OCC(CO)=CC1=CC=C([N+]([O-])=O)C=C1 QQDIKWXZOLTRDH-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010056384 CDPGYIGSR Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000004175 Cathepsin H Human genes 0.000 description 1
- 108090000619 Cathepsin H Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 229940123003 Cathepsin inhibitor Drugs 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010018907 Gly-Arg-Gly-Asp-Ser-Pro-Cys Proteins 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- AJGJROVYVKUHID-UHFFFAOYSA-N OPNP Chemical compound OPNP AJGJROVYVKUHID-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 230000010062 adhesion mechanism Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010077696 cystinyl-aspartyl-prolyl-glycyl-tyrosyl-isoleucyl-glycyl-seryl-arginyl-NH2 Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 108010022683 guanidinobenzoate esterase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention is directed to hydrolyzable prodrugs for delivery of therapeutic drugs to metastatic cells, particularly anticancer drugs.
- Metastasis is the hallmark of cancer.
- a tumor that does not metastasize is termed "benign” because it poses a threat of survival that is small compared to a "malignant" tumor that does metastasize (McGuire, New En ⁇ . J. Med.. 320:525 (1989)).
- Metastasis involves a sequence of events that few cells can successfully complete (Sanchez, Am. J. Med. ScL 292:376 (1986); Poste, Nature. 283:139 (1980)). Metastatic cells must break away from the primary tumor, survive attack by the immune system during transit in the blood, lodge somewhere while resisting the shear force of the moving blood stream, penetrate basement membrane to reach a safe haven where they can multiply, and finally create a blood supply of their own when the demand for nourishment of the growing metastatic tumor exceeds what is available locally by diffusion. Metastatic cells are not a representative sample of the tumor (itself highly heterogeneous) (Poste, Ann. New York Acad. Sci., 397:34 (1982); Heppner, Cancer Res..
- metastases are very small and therefore comparatively accessible to chemotherapy, they are highly resistant to present day drugs, for in spite of heavy medication, survival rates for e.g., phases 2 and 3 breast carcinoma (lymph node involvement signaling spread) are very low compared to phase 1 (no spread). In the absence of spread, the survival rate is 70% or greater; in the presence of spread, it is less than 10% (McGuire, New En ⁇ . J. Med.. 320:525 (1989)). Inhibiting as contrasted with killing metastases can only prolong life a short while because by the time cancer is typically diagnosed, metastasis has already taken place.
- such anti -metastatic reagents should be usable against many types of metastases and not depend for their activity on characteristics of the primary tumor cells that might not be shared by the metastases.
- such anti-metastatic reagents should be readily absorbed and lack toxicity, particularly in patients who are already subject to regimens consisting of multiple drug treatment.
- a hydrolyzable prodrug according to the present invention comprises an amino-terminal capped peptide covalently linked to a therapeutic drug through a self- immolating spacer of sufficient length to prevent the occurrence of steric hindrance.
- the amino-terminal capped peptide is a substrate for a peptidohydrolase located on the surface of a metastatic cell
- the peptidohydrolase is cathepsin B or collagenase IV.
- the peptidohydrolase is cathepsin B.
- the amino-terminal capped peptide is benzyloxycarbonylphenylalanyllysine, benzyloxycarbonylvalinyllysine, D- phenylalanylphenylalanyllysine, benzyloxycarbonylvalinylcitrulline, t-butyloxyca ⁇ >onylphenylalanylysine, benzyloxycarbonyl- alanyllarginylarginine, benzyloxycarbonylphenylalanyl-N-tosylarginine,2- aminoethylthio-succinimidopropionylvalinylcitrulline, 2-aminoethylthio- succinimidopropionyllysylphenylalanyllysine, acetylphenyialanyllysine, or benzyloxycarbonylphenylalanyl-O-benzoylthreonine.
- the therapeutic drug is an anticancer drug.
- the anticancer drug is doxorubicin, mitomycin C, taxol, esperamycin, or camptothecin.
- a particularly preferred anticancer drug is doxorubicin.
- PABC p_-aminobenzyl carbonyl
- the hydrolyzable prodrug can further comprise a peptide derived from a protein to which metastatic cells adhere in establishing colonies covalently linked to the therapeutic drug.
- the peptide is a RGD-derived active peptide or a YIGSR-derived active peptide.
- the peptide is YIGSR (SEQ ID NO:1) or GRGDS (SEQ ID NO:2).
- Preferred hydrolyzable prodrugs according to the present invention include benzyloxycarbonylphenylalanyllysyl-rj-aminobenzyl carbamoyldoxorubicin, acetylphenylalanyllysyl- ⁇ -aminobenzyl carbamoyldoxorubicin, acetylphenylalanyliysyl-g-aminobenzyl carbamoylmitomycin C, benzyloxycarbonylphenylalanyllysyl-p_-aminobenzyl carbonyl-7-paclitaxel, acetylphenylalanyllysyl-p-aminobenzyl carbonylcamptothecin, 2-aminoethylthio-succinimidopropionyl- valinyicitrullinyl-BHMS-didoxorubicin, 2-aminoethylthio- succinimidopropionyl
- Another aspect of the present invention is a method for delivering a therapeutic drug to a metastatic cell comprising the steps of: (1) contacting a hydrolyzable prodrug according to the present invention with a metastatic cell;
- composition comprising:
- Figure 1 is a depiction, showing structural formulas and reaction conditions, of the initial stages in the synthesis of the hydrolyzable prodrug Ac-Phe-Lys-PABC-Dox;
- Figure 2 is a similar depiction of the final stages in the synthesis of Ac-Phe-Lys-PABC-Dox;
- Figure 3 is a similar depiction of the synthesis of the hydrolyzable prodrug Ac-Phe-PABC-MMC, beginning with an intermediate in the synthesis of Ac-Phe-Lys-PABC-Dox prior to the coupling of the doxorubicin residue;
- Figure 4 is a similar depiction of the initial stages of the synthesis of the hydrolyzable prodrug Z-Phe-Lys-PABC-Paclitaxel
- Figure 5 is a similar depiction of the final stages of the synthesis of the hydrolyzable prodrug Z-Phe-Lys-PABC-Paclitaxel
- Figure 6 is a similar depiction of the early stages of the synthesis of the hydrolyzable prodrug CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
- Figure 7 is a similar depiction of the intermediate stages of the synthesis of CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
- Figure 8 is a similar depiction of the final stages of the synthesis of CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
- Figure 9 is a table showing the killing of BT-20 tumor cells, which are high-cathepsin B-secreting cells, and MCF-10A tumor cells, which are low-cathepsin B-secreting cells, by several hydrolyzable prodrugs and control compounds in the presence or absence of the cathepsin inhibitor CA- 074;
- Figure 10 is a table showing the killing of BT-20 tumor cells at various times and prodrug concentrations with several hydrolyzable prodrugs and a control compound;
- Figure 1 1 is a table showing the killing of BT-20 and MCF-10A tumor cells at various times and prodrug concentrations with the hydrolyzable prodrug CA-SP-Lys-Phe-Lys-BHMS-Dox 2 ;
- Figure 12 is a table showing the stability of hydrolyzable prodrugs according to the present invention under physiological conditions in the presence or absence of cathepsin B.
- One new approach to developing reagents specific for metastatic cells takes advantage of the properties of the metastatic cells themselves, particularly those properties possessed by the metastatic cells that allow them to spread through the body and adhere to specific tissues.
- One such property is the ability of metastatic cells to penetrate basement membrane (Sanchez, Am. J. Med. Sci. 292:376 (1986); Poste, Nature. 283:139 (1980)), shared only by the peripheral cells of the primary tumor (Poole, Nature. 273:545 (1978); Shamberger, Nature. 213:617 (1967); Graf, Lab. Invest.. 45:587 (1981 ); Baici, Inv. Metas.. 4:13 (1984); Duffy, Eur. J. Cancer Clin. Oncol.. 23:583 (1987)) and by virtually no normal body cells.
- Metastatic cells do this by means of hydrolytic enzymes which they secrete into the medium (Duffy, Eur. J. Can. Clin. Oncol.. 23:583 (1987); MacKay, Cancer Res.. 50:5997 (1990); Goldfarb, Sem. Thromb. Hemostas.. 12:294 (1986); Pietras, Gynec. Oncol.. 7:1 (1979)) or in their plasma membranes (Sylven, Virchows Arch. B.. 17:97 (1974); Sloane, Biomed. Biochim. Acta. 50:549 (1991 ); Keren, Cancer Res.. 48:1416 (1989); Pietras, J. Biol. Chem..
- Tumors are proteolvtic (Fischer. Arch. Entw. Mech. Arg.. 104:210 (1925); Duffy, Eur. J. Cancer Clin. Oncol.. 23:583 (1987); Strauli et al., ed., "Proteinases and Tumor Invasion” (Raven Press, New York, 1980)), and this power is correlated with metastatic propensity (Duffy, Eur. J. Cancer Clin. Oncol.. 23:583 (1987); Sylven, Virchows Arch. B.. 17:97 (1974); Sloane,
- Enzymes known to be secreted by metastasizing cells include cathepsin B (Sloane, Biomed. Biochim. Acta. 50:549 (1991 ); Keren, Cancer Res.. 48:1416 (1989); Pietras, J. Biol. Chem.. 256:8536 (1981 ); Weiss, Proc. Am. Assoc. Cancer Res...
- cytotoxic drugs at the sites of metastatic foci.
- Preferred drugs are those that are readily ingested by cells such as doxorubicin (Dox) (also known as adriamycin (ADM)), mitomycin C (MMC), taxol, camptothecin (CPT), and esperamycin, as well as derivatives of these drugs.
- Dox doxorubicin
- MMC mitomycin C
- CPT camptothecin
- esperamycin esperamycin
- anticancer drugs have substantial hydrophobic moieties so that they can pass through the plasma membrane of metastatic cells.
- Other anticancer drugs can be derivatized with appropriate hydrophobic moieties to improve their permeability to the lipid bilayer of the plasma membrane of the metastatic cell.
- a particularly useful enzyme with prodrugs according to the present invention is cathepsin B, principally because it is an exopeptidase (Takahashi, J. Biol. Chem.. 261 :9375 (1986); Koga, J. Biochem.. 110:179 (1991)) for which numerous peptide substrates are already known (Dingle, ed., “Lysosomes” (North-Holland, Amsterdam, 1977); Strauli et al., eds., “Proteinases and Tumor Invasion” (Raven Press, New York, 1980); Neuberger, ed., "Hydrolytic Enzymes” (Elsevier, Amsterdam, 1987)).
- Cathepsin B is a lysosomal enzyme that is ubiquitous within cells (Dingle, ed., “Lysosomes” (North-Holland, Amsterdam, 1977); Strauli et al., eds., “Proteinases and Tumor Invasion” (Raven Press, New York, 1980); Neuberger, ed., “Hydrolytic Enzymes” (Elsevier, Amsterdam, 1987)), but almost never secreted normally. If small amounts of cathepsin B do escape during exocytosis or unprogrammed cell death, it loses all activity within 15 minutes at neutral pH (Sheahan, Cancer Res..
- the plasma membrane is obviously a highly desirable place to activate a latent cytotoxic drug which should be delivered, not only as directly as possible to the target cells, but also to neighboring cancer cells that might not display as much cathepsin B as the majority, owing to the high genetic instability (Fidler, Cancer Treat. Rep.. 68:193 (1984)) of metastasizing cells.
- a preferred reagent for delivering therapeutic drugs to metastasizing cells is a hydrolyzable prodrug comprising an amino-terminal capped peptide covalently linked to a therapeutic drug through a self-immolating spacer of sufficient length to prevent the occurrence of steric hindrance.
- the amino-terminal capped peptide is a substrate for a peptidohydrolase located on the surface of a metastatic cell.
- the peptidohydrolase is cathepsin B or collagenase
- the peptidohydrolase is cathepsin B.
- the amino-terminal capped peptide that acts as a substrate for the peptidohydrolase is typically one of benzyloxycarbonylphenylalanyllysine, benzyloxycarbonylvalinyllysine, D-phenylalanylphenylalanyllysine, benzyloxycarbonylvalinylcitrulline, t-butyloxycarbonylphenylalanylysine, benzyloxycarbonylalanyllarginylarginine, benzyloxycarbonylphenylalanyl-N- tosylarginine,2-aminoethylthio-succinimidopropionylvalinylcitrulline, 2- aminoethylthio-succinimidopropionyllysylphenylalanyllysine,
- the amino-terminal capped peptide is benzyloxycarbonylphenylalanyllysine or acetylphenylalanyllysine.
- substrates containing paired basic residues can be hydroiyzed by cathepsin B (J.K. McDonald & S. Ellis, Life Sci.. 17:1269-1276 (1975)).
- the amino-terminal residue must be "capped” or protected with a protecting group.
- protecting groups are well-known in peptide chemistry and include, for example, benzyloxycarbonyl (also known as carbobenzoxy and generally abbreviated as Z), acetyl, 2-aminoethylthio-succinimidopropionyl, t-butyloxycarbonyl, and other amino-terminal protecting groups such as those disclosed in M. Bodanszky, "Principles of Peptide Synthesis” (2d Ed., Springer-Verlag, Berlin, 1993).
- These groups include triphenylmethyl, ⁇ - methoxybenzyloxycarbonyl, adamantyloxycarbonyl, biphenylylisopropyloxycarbonyl, formyl. isonicotinyloxycarbonyl, o- nitrophenylsulfenyl, 9-fluorenylmethyloxycarbonyl, derivatives of benzyloxycarbonyl substituted on the aromatic ring of the benzyl group, or, in some cases, in which the phenyl moiety of the benzyl group is replaced with another fully aromatic moiety such as furan or pyndine, phthaloyl, dithiasuccinyl, p-toluenesulfonyl (tosyl), and other groups.
- the amino-terminal protecting group can be a D- amino acid such as D-phenylalanine.
- the amino-terminal protecting group is a D-amino acid
- the carboxyl group of the D-amino acid forms a peptide bond with the amino-terminal residue of the amino-terminal protected peptide.
- the protecting group is benzyloxycarbonyl or acetyl, so that the amino-terminal protected peptide is benzyloxycarbonylphenylalanyllysine or acetylphenylalanyllysine.
- the hydrolyzable prodrug includes a spacer of sufficient length to prevent the occurrence of ste c hindrance between the amino-terminal protected peptide and the therapeutic drug. If the spacer is too short, the therapeutic drug may prevent the binding of the substrate for the peptidohydrolase to the active site of the peptidohydrolase by stenc hindrance.
- a particularly suitable spacer is ⁇ _-am ⁇ nobenzyl carbonyl ("PABC"). This has an approximate length of 10 angstroms.
- Derivatives of p-aminobenzyl carbonyl can also be used, such as compounds substituted on the aromatic moiety of the benzyl group.
- spacer groups can be used.
- the length of the spacer should be greater than about 10 angstroms; spacers of significantly greater length can be used, and can incorporate, for example, additional aliphatic or aromatic moieties. In general, such spacers should be relatively unbranched so as not to introduce stenc hindrance of their own.
- the chemical functionality terminating the spacer can vary but one end is able to react with the carboxyl-terminal residue of the substrate for the peptidohydrolase. Typically, this is an amino group.
- the other functionality terminating the spacer is capable of reacting with the therapeutic drug. In one preferred embodiment, this functionality reacts at an amino group of the drug to form a carbamate or urethane linkage as part of the spacer.
- This spacer also reacts at an amino group of the drug to form a carbamate or urethane linkage.
- This spacer is bifunctional and can bind two drug moieties such as doxorubicin.
- such spacers have the property of self-immolation.
- a self-immolating spacer is one in which the residual portion of the spacer attached to the therapeutic drug subsequent to the hydrolysis of the peptide bond by the peptidohydrolase is then further cleaved by spontaneous, nonenzymatic hydrolysis in an aqueous medium to restore the original unconjugated drug.
- Both PABC and BHMS are self-immolating.
- the spacer is p_-aminobenzyl carbonyl ("PABC") and the therapeutic drug is doxorubicin
- PABC p_-aminobenzyl carbonyl
- doxorubicin the portion of the spacer remaining attached to the drug after hydrolysis of the peptide bond by cathepsin B, then subsequently undergoes spontaneous hydrolysis to ⁇ _-aminobenzyl alcohol, carbon dioxide, and doxorubicin.
- the therapeutic drug is an anticancer drug.
- other therapeutic drugs can be incorporated into hydrolyzable prodrugs according to the present invention and can be delivered to metastatic cells.
- Preferred anticancer drugs incorporated into hydrolyzable prodrugs according to the present invention include doxorubicin, taxol, camptothecin, mitomycin C, and esperamycin, as well as derivatives thereof.
- Other anticancer drugs that have hydrophobic moieties that allow them to be taken up efficiently by metastatic cells or that can be derivatized with such moieties can also be used.
- hydrolyzable prodrugs include benzyloxycarbonylphenylalanyllysyl- ⁇ -aminobenzyl carbamoyldoxorubicin, acetylphenylalanyliysyl-p_-aminobenzyl carbamoyldoxorubicin, acetylphenylalanyllysyl-p_-aminobenzyl carbamoylmitomycin C, benzyloxycarbonylphenylalanyllysyl- _-aminobenzyl carbonyl-7-paclitaxel, acetylphenylalanyllysyl-p_-aminobenzyl carbonylcamptothecin, 2- aminoethylthio-succinimidopropionyl-valinylcitrullinyl-bis(hydroxymethyl)- styryl-bisdoxorubicin, 2-aminoethylthi
- Synthesis of hydrolyzable prodrugs according to the present invention can be accomplished by condensation reactions that are well known in the art. Examples of syntheses are given below in Examples 1 -6.
- the synthetic procedure comprises: (1 ) synthesizing the peptide that is the substrate of the peptidohydrolase by conventional peptide synthetic techniques, with the ⁇ -amino group of the amino-terminal amino acid residue protected and appropriate protection for reactive side chains of the amino acids; (2) linking the g-aminobenzyl moiety to the carboxyl group of the carboxyl-terminal amino acid; (3) activating the j-aminobenzyl moiety for covalent linkage of the therapeutic drug; (4) covalently linking the therapeutic drug, which may have certain reactive side chains protected as well; and (5) removing the remaining protecting groups on the peptide and the therapeutic drug.
- the synthetic procedure comprises: (1) synthesizing a peptide that is the substrate of the peptidohydrolase by conventional peptide synthetic techniques, with appropriate protective groups as above; (2) linking the BHMS moiety to the carboxyl group of the carboxyl-terminal amino acid of the peptide; (3) activating the BHMS moiety for coupling of the therapeutic drug; (4) coupling the therapeutic drug to the activated BHMS moiety; (5) removing any protecting groups on amino acid side chains, such as the ⁇ -amino group of lysine; and (6) modifying the amino-terminal blocking group so that the desired capping group is present.
- the substrate for cleavage by the peptidohydrolase is a tripeptide or peptide with more than three amino acids
- the peptide can be extended at its amino-terminus after the coupling of the carboxyl-terminus to the spacer. This involves removing the amino-terminal protecting group of the peptide, activating the carboxyl group of the amino acid to be added, and coupling it to the deblocked amino group to form a peptide bond. This step can be repeated if a longer peptide is desired. Then, the therapeutic drug is coupled to the completed peptide and synthesis of the hydrolyzable prodrug is completed as above.
- the hydrolyzable prodrug further comprises a peptide derived from a protein that adheres to metastatic cells.
- peptides include peptides derived from the protein fibronectin (GRGDS)(SEQ ID NO:1)(Humphries, Science 233:467 (1986); Olden. Ann. New York Acad. Sci. 421 (1989); Dedhar, Bjo Essays. 12:583 (1990)) and laminin (YIGSR)(SEQ ID NO:2)(lwamoto, Science. 238:1132 (1987); Saiki, Brit. J. Cancer 59:194 (1989)).
- GAGDS protein fibronectin
- YIGSR laminin
- the peptide is covalently linked to the amino side of the amino-terminal capped peptide that is the substrate for the peptidohydrolase, either directly as an amide, or indirectly via attachment to the capping group, benzyloxycarbonyl, acetyl, maleimidopropionyl or the like, which has been modified to accept the peptide.
- the linkage can be through either the amino or carboxyl group of the peptide, or, in some cases, through functional groups of the peptide such as the carboxyl of aspartic acid, the hydroxyl of serine or other functional groups of other residues.
- various cross-linking reagents can be used.
- carbodiimides such as dicyclohexylcarbodiimide
- Other reactive groups are known and are described, for example, in G.T. Hermanson, "Bioconjugate Techniques” (Academic Press, San Diego, 1996), in S.S. Wong, “Chemistry of Protein Conjugation and Crosslinking” (CRC Press, Boca Raton, Fla. 1991), and in T.E. Creighton, Ed., "Protein Function: A Practical Approach” (IRL Press, Oxford 1989).
- the peptide can be linked, for example, to a maleimidopropionyl cap via a cysteine whose thiol group is added to the maleimido group, or to a glycine or other amino acid cap (replacing the acetyl cap) via acylation of the amino group of the glycine, or by attaching the peptide to the reposition of the benzyloxycarbonyl cap, or by other methods known to the art.
- the linkage of these peptides such as YIGSR (SEQ ID NO: 2) to the prodrug may be with or without intervening links which might or might not consist of other amino acids.
- conjugation or crosslinking methods can also be used to attach the peptides such as the peptides from laminin or fibronectin to other portions of the hydrolyzable prodrug,. tn most cases, attaching the peptide to the self-immolating spacer would either prevent hydrolysis of the substrate by the peptidohydrolase or result in steric hindrance.
- a number of peptides derived from the fibronectin and laminin peptides can be linked to the hydrolyzable prodrugs. These peptides can be classified in terms of their structure and homology to the fibronectin or laminin sequence as follows:
- Fibronectin-derived peptides include: (1) the GRDGS (SEQ ID NO: 1) pentapeptide derived from the fibronectin sequence (I. Hardan et al., "Inhibition of Metastatic Cell Colonization in Murine Lungs and Tumor- Induced Morbidity by Non-Peptidic Arg-Gly-Asp Mimetics," Int. J. Cancer 55: 1023-1028 (1993)); (2) derivatives of the fibronectin pentapeptide sequence with conservative amino acid substitutions, such as GRGES (SEQ ID NO: 3) (R.J.
- GRGDSPA SEQ ID NO: 8
- GRGDXPC extended peptides with ammo acid substitutions, such as GRGDXPC, where X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
- GRGDNPC SEQ ID NO: 9
- GRGDXPA GRGDXPA
- X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
- GRGDSG SEQ ID NO: 1 1
- YIGSR Multimeric Forms of Tyr-lle-Gly-Ser-Arg
- GRGDXG where X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
- GRDGXPA where X is a naturally-occurring L-amino acid other than M, C, H, Y, G, or P
- Laminin-derived peptides include: (1 ) the YIGSR (SEQ ID NO:
- CDPGYIGSR SEQ ID NO: 17
- peptides including substituted peptides and extended sequences with amino acid substitutions, in which a D-amino acid replaces one of the naturally occurring L-amino acids, such as CDPGYI(dA)SR and YIG(dA)SR (G.J. Ostheimer et al., "NMR Constrained Solution Structures for Laminin Peptide 11.” J. Biol. Chem.
- An additional aspect of the present invention is a method for delivery of a therapeutic drug to a metastatic cell.
- a method for delivery of a therapeutic drug to a metastatic cell comprises the steps of:
- a hydrolyzable prodrug comprising an amino- terminal capped peptide covalently linked to a therapeutic drug through a self-immolating spacer of sufficient length to prevent the occurrence of steric hindrance with a metastatic cell, the amino-terminal capped peptide being a substrate for a peptidohydrolase located on the surface of the metastatic cell;
- the therapeutic drug is an anticancer drug.
- the hydrolyzable prodrug is delivered to the metastatic cells under conditions under which the prodrug is stable in the absence of enzymatic hydrolysis.
- prodrugs are stable in plasma at pH 7.4 at 37 9 C. for at least 6 days in the absence of a peptidohydrolase such as cathepsin B.
- the prodrugs are stable for 16 days or more or 20 days or more in the absence of cathepsin B.
- the prodrug can be delivered to the metastatic cells either in vivo or in vitro.
- the hydrolyzable prodrugs of the present invention are administered in a quantity sufficient to kill at least a fraction of the metastatic cells.
- the hydrolyzable prodrugs of the present invention can be administered in vivo using conventional modes of administration including, but not limited to, intravenous, intraperitoneal, oral or intralymphatic. Other routes of injection can alternatively be used. Oral or intraperitoneal administration is generally preferred.
- the composition can be administered in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred dosage form depends on the mode of administration and the quantity administered.
- compositions for administration according to the present can include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
- conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
- the most effective modes of administration and dosage regimen for the hydrolyzable prodrugs as used in the methods of the present invention depend on the severity and course of the disease, the patient's health, the response to treatment, the particular type of metastatic cells characteristic of the particular primary tumor, the location of the metastases, pharmacokinetic considerations such as the condition of the patient's liver and/or kidneys that can affect the metabolism and/or excretion of the administered hydrolyzable prodrugs, and the judgment of the treating physician. Accordingly, the dosages should be titrated to the individual patient.
- the invention is further exemplified by the following Examples. These examples are for illustrative purposes only and are not intended to limit the scope of the invention.
- hydrolyzable prodrug is acetylphenyialanyllysyl-p-aminobenzyl carbonylcamptothecin (Ac-Phe-Lys-PABC-CPT).
- Fmoc-Phe-Lys-(Boc)- PABC-CPT 200 mg, 0.18 mmol was suspended in 6.0 mi of methylene chloride and 1.0 ml of diethylamine added. The suspension gradually dissolved as the solution and was stirred for 3 h. The solvent and diethylamine were removed under vacuum. The resulting foamy solid was redissolved in methylene chloride and then acetic anhydride (0.068 ml, 0.72 mmol) and diisopropylethylamine (0.13 mol) added. The reaction mixture was stirred overnight, transferred to a separatory funnel, and washed with pH 7 buffer.
- This bifunctional spacer can bind two doxorubicin molecules.
- This compound also has a capping group of 2-aminoethylthio (CA) linked to the valine residue through a succinimidopropionyl (SP) group.
- CA 2-aminoethylthio
- SP succinimidopropionyl
- Fmoc-Lys The first step in the synthesis of the hydrolyzable prodrug Ac-Phe-Lys-PABC-Dox is the synthesis of Fmoc- Lys (MMT).
- This lysine derivative has its ⁇ -amino group protected with the protecting group 9-fluorenylmethoxycarbonyl and its ⁇ -amino group protected with the blocking group monomethoxytrityl.
- hydrolyzable prodrug according to the present invention with an acetyl capping group and mitomycin C (MMC) as the anticancer drug was synthesized.
- the peptide substrate for cathepsin B is Phe-Lys. Synthesis of Ac-Phe-Lvs(MMT)-PABC-MMC.
- the first step in the synthesis is the coupling of the phenylalanyl moiety with the lysine moiety, whose ⁇ - amino group is protected with a monomethoxytrityl (MMT) residue. Coupling is accomplished with the use of a succinimidyi derivative of the phenylalanine, whose carboxyl group is thereby activated.
- the first step in the synthesis of the bifunctional hydrolyzable prodrug CA-SP- Lys-Phe-Lys-BHMS-Dox 2 is a synthesis of the bifunctional linker bis(hydroxymethyl)p_-aminostyrene (BHMS).
- Raney nickel (5.28 ml, 50% slurry in H 2 0) and hydrazine monohydrate (21 ml, 1.5 equiv.) were added to a stirred solution of 2-(p-nitrobenzylidene)-propane-1 ,3-diol (P. Vanelle et al., Eur. J. Med. Chem.
- the BT-20 cell line was maintained in E-MEM-10 (minimal essential medium (Earle's Salts) supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 ⁇ g/ml)) in 5% C0 2 at 37° C.
- E-MEM-10 minimal essential medium (Earle's Salts) supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 ⁇ g/ml)
- MCF 10A cell line was maintained in DMEM/Ham's F12 supplemented with 5% horse serum, EGF (20 ng/ml), insulin (0 5 ⁇ g/ml), hydrocortisone (0.5 ⁇ g/ml), penicillin (100 U/ml), and streptomycin (100 ⁇ g/ml) in 5% C0 2 at 37 9 C Corning tissue culture multiwell plates (24 wells/plate) were seeded with 10 5 cells/16 mm well in 2 ml maintenance medium, refed 48 h after seeding and were ready to use in cytotoxicity assays 4 8h later, with the cells just reaching confiuency.
- cytotoxicity assay protocol employing MCF 10A (low cathepsin B secreters) and BT-20 (high cathepsin B secreters) and inhibition of cytotoxicity with L- trans-epoxysuccmyl-leucylamido (4-guan ⁇ do) butane (cysteine protease inhibitor) or CA-074 (N-(L-3-trans-propylcarbamoylox ⁇ rane-2-carbonyl)-L- ⁇ soleucyl-L-prol ⁇ ne)(spec ⁇ f ⁇ c cathepsin B inhibitor) was standardized with the only variations occurring with compound, molar concentration, time of exposure, and presence or absence of inhibitors Maintenance medium was aspirated from the cell walls after feeding, and the cells washed twice with 2 ml/well Hanks balanced salt solution (HBSS).
- HBSS Hanks balanced salt solution
- Compound (1) was Ac-Phe-Lys-PABC-Dox
- Compound (2) was Ac-Phe-Lys-PABC-MMC
- Compound (3) was Ac-Phe- Lys-PABC-CPT
- Compound (4) was Z-Phe-Lys-PABC-7-Paclitaxel
- Compound (5) was CA-SP-Val-Cit-BHMS-Dox 2
- Compound (6) was CA- SP-Lys-Phe-Lys-BHMS-Dox 2
- Compound (7) was Z-Phe-Lys-Dox
- Compound (8) was 2-Hydroxyethytthio-SP-D-Phe-Lys-PABC-Dox.
- MMC is mitomycin C
- CPT is camptothecin
- Z is benzyloxycarbonyl
- CA is 2-aminoethylthio
- SP is succinimidopropionyl
- PABC is p_-aminobenzyl carbonyl
- CA-074 The killing of high cathepsin B-secreting cells was inhibited by CA-074.
- CA-074 does not inhibit this killing because it does not enter lysosomes.
- Compounds (7) and (8) are control compounds, weaker cytotoxic agents than Compounds (1) and (2) because they are less susceptible to cathepsin B- mediated hydrolysis to an active drug because of their particular structures.
- Compound (7) lacks the PABC-self-immolating linker that facilitates enzymatic cleavage, resulting in probable steric hindrance that places the bulky doxorubicin moiety in the active site of the cathepsin B.
- Compound (8) has the amino acids in the unnatural D instead of the natural L configuration.
- Figure 10 depicts the percent cell kill at various times and prodrug concentrations with BT-20 cells.
- the results with CA-074 present at 40 ⁇ M are given in parentheses. The results indicate that all test compounds show dose- and time-dependent killing of BT-20 (cathepsin B+) ceils.
- the cathepsin B inhibitor CA-074 strongly inhibits cytotoxicity.
- Compound (8), the compound containing the amino acids in the D- configuration, is very much less active.
- tumor cells do indeed secrete enough cathepsin B to release enough cytotoxic drug to kill the cells efficiently. Tumor cells that secrete less cathepsin B are resistant to the hydrolyzable prodrugs.
- Cathepsin B inhibitors strongly reduce cytotoxicity of the prodrugs, showing that cathepsin B is the principal means of unmasking them.
- a prodrug lacking the self-immolating linkers PABC or BHMS has much reduced cytotoxicity, showing that it is an enzyme, presumably cathepsin B, that releases active drug. This is because the absence of the self-immolating linker results in steric hindrance.
- a prodrug with amino acids in the unnatural D configuration has much reduced cytotoxicity, again showing the role of cathepsin B.
- Figure 12 shows the stability of a number of hydrolyzable prodrugs according to the present invention linked to doxorubicin using a PABC-self-immolating linker.
- These hydrolyzable prodrugs release anticancer drug under cathepsin B catalysis at 37°C, pH 7.4, at reasonable rates, and are stable for days or weeks in freshly drawn human plasma under the same conditions.
- the present invention provides an efficient way to treat cancer cells secreting peptidohydrolases on their surface, particularly metastatic cells.
- the hydrolyzable prodrugs of the present invention are usable against many types of metastases and do not depend for their activity on characteristics of the primary tumor cells that might not be shared by the metastases. Hydrolyzable prodrugs of the present invention are readily absorbed and lack toxicity.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97944519A EP0961619A4 (en) | 1996-09-27 | 1997-09-25 | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
AU45995/97A AU739028B2 (en) | 1996-09-27 | 1997-09-25 | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
CA002264227A CA2264227A1 (en) | 1996-09-27 | 1997-09-25 | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
JP10515981A JP2001501211A (en) | 1996-09-27 | 1997-09-25 | Hydrolysable prodrugs for delivery of anticancer drugs to metastatic cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4433496P | 1996-09-27 | 1996-09-27 | |
US60/044,334 | 1996-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998013059A1 true WO1998013059A1 (en) | 1998-04-02 |
Family
ID=21931799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/017410 WO1998013059A1 (en) | 1996-09-27 | 1997-09-25 | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0961619A4 (en) |
AU (1) | AU739028B2 (en) |
CA (1) | CA2264227A1 (en) |
WO (1) | WO1998013059A1 (en) |
Cited By (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999025729A1 (en) * | 1997-11-18 | 1999-05-27 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
WO2000001417A1 (en) * | 1998-07-03 | 2000-01-13 | Cyclacel Limited | Delivery system |
WO2000069472A2 (en) * | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
WO2000071571A2 (en) * | 1999-05-14 | 2000-11-30 | Boehringer Ingelheim Pharma Kg | Fap-activated anti-tumor compounds |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6214330B1 (en) | 1998-07-13 | 2001-04-10 | Enzon, Inc. | Coumarin and related aromatic-based polymeric prodrugs |
US6303569B1 (en) | 1997-12-30 | 2001-10-16 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6310039B1 (en) | 1996-09-11 | 2001-10-30 | Felix Kratz | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
WO2002008174A1 (en) * | 2000-07-26 | 2002-01-31 | Patrick Anthony Riley | Phenylethylamine derivatives and their use in the treatment of melanoma |
US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
WO2002042295A2 (en) * | 2000-11-01 | 2002-05-30 | Praecis Pharmaceuticals Inc. | Peptides as met-ap2 inhibitors |
US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
JP2002537347A (en) * | 1999-02-24 | 2002-11-05 | ザ ユーエイビー リサーチ ファンデイション | Texane derivatives for targeted therapy of cancer |
JP2003508502A (en) * | 1999-09-07 | 2003-03-04 | コンジュケム,インコーポレーテッド | Methods and compositions for the production of long-lasting antineoplastic agents |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
WO2003043631A2 (en) * | 2001-11-23 | 2003-05-30 | Chugai Seiyaku Kabushiki Kaisha | Method for identification of tumor targeting enzymes |
WO2003068934A2 (en) * | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
WO2004019993A1 (en) * | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
EP1399467A2 (en) * | 2001-05-09 | 2004-03-24 | NewBiotics, Inc. | Peptide deformylase activated prodrugs |
US6720306B2 (en) | 1997-12-17 | 2004-04-13 | Enzon Pharmaceuticals, Inc. | Tetrapartate prodrugs |
WO2004043493A1 (en) * | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
US6835807B1 (en) | 1998-05-22 | 2004-12-28 | Daiichi Pharmaceuticals Co., Ltd. | Drug complex and drug delivery system |
US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
US6933302B2 (en) | 2002-06-03 | 2005-08-23 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7001922B2 (en) | 2002-11-14 | 2006-02-21 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
EP1672978A2 (en) * | 2003-09-10 | 2006-06-28 | Manticore Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
US7101967B2 (en) | 1998-11-13 | 2006-09-05 | Cyclacel Limited | Transport vectors |
US7105482B2 (en) | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
US7157420B2 (en) | 2000-11-01 | 2007-01-02 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
EP1982720A1 (en) | 2002-05-20 | 2008-10-22 | The Regents of the University of California | Ribaviren for use to treat cancer |
WO2009006613A1 (en) | 2007-07-03 | 2009-01-08 | Children's Hospital & Research Center At Oakland | Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
EP2093235A1 (en) | 2006-02-08 | 2009-08-26 | Alios Biopharma Inc. | Hyperglycosylated variants of interferon alfacon-1 |
US7608591B2 (en) | 2003-05-29 | 2009-10-27 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
WO2009143454A2 (en) | 2008-05-22 | 2009-11-26 | Kereos, Inc. | Combination antitumor therapy |
WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
EP2260858A2 (en) | 2003-11-06 | 2010-12-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US7875602B2 (en) | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
EP2281006A1 (en) * | 2008-04-30 | 2011-02-09 | Immunogen, Inc. | Cross-linkers and their uses |
US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
EP2327705A1 (en) | 2001-12-03 | 2011-06-01 | Universitätsklinikum Charité der Humboldt- Universität zu Berlin | Podophyllotoxins as antiproliferative agents |
EP2353611A2 (en) | 2002-07-31 | 2011-08-10 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US8022047B2 (en) | 2005-08-22 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Combination anticancer agents |
WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
CN102504013A (en) * | 2011-09-28 | 2012-06-20 | 李雁 | Target chemical drug PADM against cancer metastasis and preparation method and use thereof |
WO2013122751A1 (en) * | 2012-02-16 | 2013-08-22 | Firestone, Raymond, A. | Compositions and methods for contraception |
WO2013109675A3 (en) * | 2012-01-18 | 2013-09-19 | FIRESTONE, Raymond, A | Compositions and methods for treating cancer and inflammation-related diseases and conditions |
WO2013173756A1 (en) | 2012-05-18 | 2013-11-21 | University Of North Dakota | A method for quantifying proteins and isoforms thereof |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
US8691780B2 (en) | 2005-02-17 | 2014-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
WO2014057113A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057117A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
EP2722051A1 (en) | 2005-07-07 | 2014-04-23 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
WO2014066498A1 (en) | 2012-10-23 | 2014-05-01 | Vivek Mittal | Treatment of metastatic breast cancer |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
WO2015038426A1 (en) * | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016166304A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
US9579390B2 (en) | 2012-11-12 | 2017-02-28 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
WO2017083637A1 (en) | 2015-11-12 | 2017-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
WO2017087723A1 (en) | 2015-11-19 | 2017-05-26 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
WO2017132103A2 (en) | 2016-01-29 | 2017-08-03 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
US9732155B2 (en) | 2011-11-04 | 2017-08-15 | Zymeworks Inc. | Crystal structures of heterodimeric Fc domains |
WO2017178456A1 (en) | 2016-04-11 | 2017-10-19 | Greenaltech, S.L | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
WO2018017190A2 (en) | 2016-06-01 | 2018-01-25 | Baxalta Incorporated | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
EP3300745A1 (en) | 2013-02-15 | 2018-04-04 | The Regents of the University of California | Chimeric antigen receptor and methods of use thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10017580B2 (en) | 2014-04-15 | 2018-07-10 | ADC Therpeutics S.A. | Humanized anti-Tn-MUC1 antibodies and their conjugates |
WO2018136570A1 (en) | 2017-01-18 | 2018-07-26 | F1 Oncology, Inc. | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
CN108383757A (en) * | 2018-04-12 | 2018-08-10 | 江苏金斯瑞生物科技有限公司 | A kind of preparation method of N ε-tertbutyloxycarbonyl-N α-fluorenylmethyloxycarbonyl-N ε-methyl-lysine |
EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
WO2019084057A2 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3505188A1 (en) | 2017-12-29 | 2019-07-03 | Invivogen | Pro-cyclic dinucleotide conjugates for cytokine induction |
WO2019152661A1 (en) | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US10550190B2 (en) | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2020206033A1 (en) | 2019-04-02 | 2020-10-08 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
WO2020245283A1 (en) | 2019-06-07 | 2020-12-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
WO2021155028A1 (en) | 2020-01-29 | 2021-08-05 | Kenjockety Biotechnology, Inc. | Anti-mdr1 antibodies and uses thereof |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2021247426A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
WO2021247423A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
WO2022043256A1 (en) | 2020-08-23 | 2022-03-03 | Cobiores Nv | Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents |
WO2022051390A1 (en) | 2020-09-02 | 2022-03-10 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
WO2022103603A1 (en) | 2020-11-13 | 2022-05-19 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2022136586A1 (en) | 2020-12-22 | 2022-06-30 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
US11510993B2 (en) | 2015-10-06 | 2022-11-29 | Merck Sharp & Dohme Llc | Antibody drug conjugate for anti-inflammatory applications |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11660266B2 (en) | 2018-04-11 | 2023-05-30 | Ohio State Innovation Foundation | Methods and compositions for sustained release microparticles for ocular drug delivery |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
WO2023194539A1 (en) | 2022-04-07 | 2023-10-12 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
US12006370B2 (en) | 2018-07-23 | 2024-06-11 | Heidelberg Pharma Research Gmbh | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
US12064446B2 (en) | 2015-04-10 | 2024-08-20 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
US12121590B2 (en) | 2023-06-06 | 2024-10-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703107A (en) * | 1983-05-16 | 1987-10-27 | Centre National De La Recherche Scientifique (Cnrs) | Water-soluble acylated derivatives of peptides or amino acids, their preparation and their use |
EP0624377A2 (en) * | 1993-05-14 | 1994-11-17 | Bristol-Myers Squibb Company | Lysosomal enzyme-cleavable antitumor drug conjugates |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001505194A (en) * | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | Branched peptide linker |
-
1997
- 1997-09-25 WO PCT/US1997/017410 patent/WO1998013059A1/en not_active Application Discontinuation
- 1997-09-25 AU AU45995/97A patent/AU739028B2/en not_active Ceased
- 1997-09-25 CA CA002264227A patent/CA2264227A1/en not_active Abandoned
- 1997-09-25 EP EP97944519A patent/EP0961619A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703107A (en) * | 1983-05-16 | 1987-10-27 | Centre National De La Recherche Scientifique (Cnrs) | Water-soluble acylated derivatives of peptides or amino acids, their preparation and their use |
EP0624377A2 (en) * | 1993-05-14 | 1994-11-17 | Bristol-Myers Squibb Company | Lysosomal enzyme-cleavable antitumor drug conjugates |
Non-Patent Citations (2)
Title |
---|
CASTRONOVO V, SOBEL M E: "LAMININ AND FIBRONECTIN INCREASE THE STAEDY STATE LEVEL OF THE 67 KD HIGH AFFINITY METASTASIS-ASSOCIATED LAMININ RECEPTOR MRNA IN HUMAN CANCER CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 168, no. 03, 16 May 1990 (1990-05-16), US, pages 1110 - 1117, XP002948779, ISSN: 0006-291X, DOI: 10.1016/0006-291X(90)91144-H * |
See also references of EP0961619A4 * |
Cited By (216)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6310039B1 (en) | 1996-09-11 | 2001-10-30 | Felix Kratz | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
US6709679B2 (en) | 1996-09-11 | 2004-03-23 | Felix Kratz | Antineoplastic conjugates of transferin, albumin and polyethylene glycol |
WO1999025729A1 (en) * | 1997-11-18 | 1999-05-27 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6720306B2 (en) | 1997-12-17 | 2004-04-13 | Enzon Pharmaceuticals, Inc. | Tetrapartate prodrugs |
US6303569B1 (en) | 1997-12-30 | 2001-10-16 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US6835807B1 (en) | 1998-05-22 | 2004-12-28 | Daiichi Pharmaceuticals Co., Ltd. | Drug complex and drug delivery system |
WO2000001417A1 (en) * | 1998-07-03 | 2000-01-13 | Cyclacel Limited | Delivery system |
US6992169B2 (en) | 1998-07-03 | 2006-01-31 | Cyclacel Limited | Carrier based drug delivery system |
US6472507B1 (en) | 1998-07-03 | 2002-10-29 | Cyclacel Limited | Carrier based drug delivery system |
US6214330B1 (en) | 1998-07-13 | 2001-04-10 | Enzon, Inc. | Coumarin and related aromatic-based polymeric prodrugs |
US7101967B2 (en) | 1998-11-13 | 2006-09-05 | Cyclacel Limited | Transport vectors |
US7153931B1 (en) | 1998-11-13 | 2006-12-26 | Cyclacel Limited | Transport vectors |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
JP4808846B2 (en) * | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | Taxane derivatives for targeted treatment of cancer |
JP2002537347A (en) * | 1999-02-24 | 2002-11-05 | ザ ユーエイビー リサーチ ファンデイション | Texane derivatives for targeted therapy of cancer |
WO2000071571A3 (en) * | 1999-05-14 | 2001-09-07 | Boehringer Sohn Ingelheim | Fap-activated anti-tumor compounds |
WO2000069472A2 (en) * | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
US6855689B2 (en) | 1999-05-14 | 2005-02-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
WO2000071571A2 (en) * | 1999-05-14 | 2000-11-30 | Boehringer Ingelheim Pharma Kg | Fap-activated anti-tumor compounds |
US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
WO2000069472A3 (en) * | 1999-05-14 | 2001-05-31 | Boehringer Ingelheim Pharma | Enzyme-activated anti-tumor prodrug compounds |
JP2003508502A (en) * | 1999-09-07 | 2003-03-04 | コンジュケム,インコーポレーテッド | Methods and compositions for the production of long-lasting antineoplastic agents |
WO2002008174A1 (en) * | 2000-07-26 | 2002-01-31 | Patrick Anthony Riley | Phenylethylamine derivatives and their use in the treatment of melanoma |
US7157420B2 (en) | 2000-11-01 | 2007-01-02 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US7037890B2 (en) | 2000-11-01 | 2006-05-02 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US7348307B2 (en) | 2000-11-01 | 2008-03-25 | Praecis Pharmaceuticals Incorporated | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
US7105482B2 (en) | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
US7268111B2 (en) | 2000-11-01 | 2007-09-11 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US7405194B2 (en) | 2000-11-01 | 2008-07-29 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the treatment of melanoma |
WO2002042295A3 (en) * | 2000-11-01 | 2003-02-20 | Praecis Pharm Inc | Peptides as met-ap2 inhibitors |
WO2002042295A2 (en) * | 2000-11-01 | 2002-05-30 | Praecis Pharmaceuticals Inc. | Peptides as met-ap2 inhibitors |
USRE39707E1 (en) | 2001-01-18 | 2007-06-26 | Catholic Healthcare West | Camptothecin derivatives |
US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US7223837B2 (en) | 2001-03-23 | 2007-05-29 | Syntarga B.V. | Elongated and multiple spacers in activatible prodrugs |
WO2002083180A1 (en) * | 2001-03-23 | 2002-10-24 | Syntarga B.V. | Elongated and multiple spacers in activatible prodrugs |
US7163923B2 (en) | 2001-05-09 | 2007-01-16 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
EP1399467A4 (en) * | 2001-05-09 | 2004-09-15 | Newbiotics Inc | Peptide deformylase activated prodrugs |
AU2002314773B2 (en) * | 2001-05-09 | 2008-05-01 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
EP1399467A2 (en) * | 2001-05-09 | 2004-03-24 | NewBiotics, Inc. | Peptide deformylase activated prodrugs |
WO2003043631A2 (en) * | 2001-11-23 | 2003-05-30 | Chugai Seiyaku Kabushiki Kaisha | Method for identification of tumor targeting enzymes |
WO2003043631A3 (en) * | 2001-11-23 | 2004-10-21 | Chugai Pharmaceutical Co Ltd | Method for identification of tumor targeting enzymes |
EP2327705A1 (en) | 2001-12-03 | 2011-06-01 | Universitätsklinikum Charité der Humboldt- Universität zu Berlin | Podophyllotoxins as antiproliferative agents |
AU2003217415B2 (en) * | 2002-02-14 | 2009-01-08 | William J Rutter | Chimeric molecules for cleavage in a treated host |
WO2003068934A2 (en) * | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
WO2003068934A3 (en) * | 2002-02-14 | 2007-02-08 | William J Rutter | Chimeric molecules for cleavage in a treated host |
EP1982720A1 (en) | 2002-05-20 | 2008-10-22 | The Regents of the University of California | Ribaviren for use to treat cancer |
US6933302B2 (en) | 2002-06-03 | 2005-08-23 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
EP2357006A2 (en) | 2002-07-31 | 2011-08-17 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP2353611A2 (en) | 2002-07-31 | 2011-08-10 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004019993A1 (en) * | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
WO2004043493A1 (en) * | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
US7001922B2 (en) | 2002-11-14 | 2006-02-21 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
US7705045B2 (en) | 2002-11-14 | 2010-04-27 | Syntarga, B.V. | Prodrugs built as multiple self-elimination-release spacers |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US7608591B2 (en) | 2003-05-29 | 2009-10-27 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
US7232805B2 (en) | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
EP1672978A4 (en) * | 2003-09-10 | 2006-12-20 | Inflabloc Pharmaceuticals Inc | Cobalamin conjugates for anti-tumor therapy |
EP1672978A2 (en) * | 2003-09-10 | 2006-06-28 | Manticore Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
EP2260858A2 (en) | 2003-11-06 | 2010-12-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP3120861A1 (en) | 2003-11-06 | 2017-01-25 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
EP2489364A1 (en) | 2003-11-06 | 2012-08-22 | Seattle Genetics, Inc. | Monomethylvaline compounds onjugated to antibodies |
EP2486933A1 (en) | 2003-11-06 | 2012-08-15 | Seattle Genetics, Inc. | Monomethylvaline compounds conjugated with antibodies |
EP3858387A1 (en) | 2003-11-06 | 2021-08-04 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP2478912A1 (en) | 2003-11-06 | 2012-07-25 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP1718667A2 (en) * | 2004-02-23 | 2006-11-08 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7754681B2 (en) | 2004-02-23 | 2010-07-13 | Seattle Genetics, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP1718667A4 (en) * | 2004-02-23 | 2009-04-08 | Genentech Inc | Heterocyclic self-immolative linkers and conjugates |
US7989434B2 (en) | 2004-02-23 | 2011-08-02 | Seattle Genetics, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
US8691780B2 (en) | 2005-02-17 | 2014-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
EP2722051A1 (en) | 2005-07-07 | 2014-04-23 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
EP3498289A1 (en) | 2005-07-07 | 2019-06-19 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
US8022047B2 (en) | 2005-08-22 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Combination anticancer agents |
US8779138B2 (en) | 2005-10-21 | 2014-07-15 | Sutter West Bay Hospital | Camptothecin derivatives as chemoradiosensitizing agents |
US7875602B2 (en) | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
US8563537B2 (en) | 2005-10-21 | 2013-10-22 | Sutter West Bay Hospital | Camptothecin derivatives as chemoradiosensitizing agents |
EP2093235A1 (en) | 2006-02-08 | 2009-08-26 | Alios Biopharma Inc. | Hyperglycosylated variants of interferon alfacon-1 |
WO2009006613A1 (en) | 2007-07-03 | 2009-01-08 | Children's Hospital & Research Center At Oakland | Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting |
EP2281006A4 (en) * | 2008-04-30 | 2012-09-19 | Immunogen Inc | Cross-linkers and their uses |
US9498541B2 (en) | 2008-04-30 | 2016-11-22 | Immunogen, Inc. | Cross-linkers and their uses |
US9061995B2 (en) | 2008-04-30 | 2015-06-23 | Immunogen, Inc. | Cross-linkers and their uses |
US8613930B2 (en) | 2008-04-30 | 2013-12-24 | Immunogen, Inc. | Cross-linkers and their uses |
CN104524592A (en) * | 2008-04-30 | 2015-04-22 | 伊缪诺金公司 | Cross-linkers and their uses |
EP2281006A1 (en) * | 2008-04-30 | 2011-02-09 | Immunogen, Inc. | Cross-linkers and their uses |
US11046762B2 (en) | 2008-04-30 | 2021-06-29 | Immunogen, Inc. | Cross-linkers and their uses |
US10494431B2 (en) | 2008-04-30 | 2019-12-03 | Immunogen, Inc. | Cross-linkers and their uses |
EP2859916A2 (en) | 2008-05-22 | 2015-04-15 | Galera Therapeutics, LLC | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy |
WO2009143454A2 (en) | 2008-05-22 | 2009-11-26 | Kereos, Inc. | Combination antitumor therapy |
WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN102504013B (en) * | 2011-09-28 | 2014-03-26 | 李雁 | Target chemical drug PADM against cancer metastasis and preparation method and use thereof |
CN102504013A (en) * | 2011-09-28 | 2012-06-20 | 李雁 | Target chemical drug PADM against cancer metastasis and preparation method and use thereof |
US9988460B2 (en) | 2011-11-04 | 2018-06-05 | Zymeworks Inc. | Crystal structures of heterodimeric Fc domains |
US9732155B2 (en) | 2011-11-04 | 2017-08-15 | Zymeworks Inc. | Crystal structures of heterodimeric Fc domains |
WO2013109675A3 (en) * | 2012-01-18 | 2013-09-19 | FIRESTONE, Raymond, A | Compositions and methods for treating cancer and inflammation-related diseases and conditions |
WO2013122751A1 (en) * | 2012-02-16 | 2013-08-22 | Firestone, Raymond, A. | Compositions and methods for contraception |
WO2013173756A1 (en) | 2012-05-18 | 2013-11-21 | University Of North Dakota | A method for quantifying proteins and isoforms thereof |
US9470693B2 (en) | 2012-05-18 | 2016-10-18 | University Of North Dakota | Method for quantifying proteins and isoforms thereof |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10780181B2 (en) | 2012-10-12 | 2020-09-22 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057113A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
US10799596B2 (en) | 2012-10-12 | 2020-10-13 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057117A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
US11771775B2 (en) | 2012-10-12 | 2023-10-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11701430B2 (en) | 2012-10-12 | 2023-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11779650B2 (en) | 2012-10-12 | 2023-10-10 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US10994023B2 (en) | 2012-10-12 | 2021-05-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US10722594B2 (en) | 2012-10-12 | 2020-07-28 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
US11690918B2 (en) | 2012-10-12 | 2023-07-04 | Medimmune Limited | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
US10646584B2 (en) | 2012-10-12 | 2020-05-12 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2014066498A1 (en) | 2012-10-23 | 2014-05-01 | Vivek Mittal | Treatment of metastatic breast cancer |
US9579390B2 (en) | 2012-11-12 | 2017-02-28 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3613439A1 (en) | 2013-02-15 | 2020-02-26 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
EP3300745A1 (en) | 2013-02-15 | 2018-04-04 | The Regents of the University of California | Chimeric antigen receptor and methods of use thereof |
EP4303232A2 (en) | 2013-02-15 | 2024-01-10 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
EP3881868A1 (en) | 2013-02-15 | 2021-09-22 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
WO2015038426A1 (en) * | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
US10550190B2 (en) | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
US10017580B2 (en) | 2014-04-15 | 2018-07-10 | ADC Therpeutics S.A. | Humanized anti-Tn-MUC1 antibodies and their conjugates |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US12064446B2 (en) | 2015-04-10 | 2024-08-20 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
WO2016166304A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
US11773150B2 (en) | 2015-10-05 | 2023-10-03 | Merck Sharp & Dohme Llc | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
US11510993B2 (en) | 2015-10-06 | 2022-11-29 | Merck Sharp & Dohme Llc | Antibody drug conjugate for anti-inflammatory applications |
WO2017083637A1 (en) | 2015-11-12 | 2017-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
WO2017087723A1 (en) | 2015-11-19 | 2017-05-26 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US11883500B2 (en) | 2016-01-29 | 2024-01-30 | Merck Sharp & Dohme Llc | Phosphonate linkers and their use to facilitate cellular retention of compounds |
US11554172B2 (en) | 2016-01-29 | 2023-01-17 | Merck Sharp & Dohme Llc | Phosphonate linkers and their use to facilitate cellular retention of compounds |
WO2017132103A2 (en) | 2016-01-29 | 2017-08-03 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
US10869929B2 (en) | 2016-01-29 | 2020-12-22 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2017178456A1 (en) | 2016-04-11 | 2017-10-19 | Greenaltech, S.L | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
US11788066B2 (en) | 2016-04-26 | 2023-10-17 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
WO2018017190A2 (en) | 2016-06-01 | 2018-01-25 | Baxalta Incorporated | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
EP4019007A1 (en) | 2016-06-01 | 2022-06-29 | Servier IP UK Limited | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2018136570A1 (en) | 2017-01-18 | 2018-07-26 | F1 Oncology, Inc. | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11813335B2 (en) | 2017-02-08 | 2023-11-14 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11938192B2 (en) | 2017-06-14 | 2024-03-26 | Medimmune Limited | Dosage regimes for the administration of an anti-CD19 ADC |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2019084057A2 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
EP3505188A1 (en) | 2017-12-29 | 2019-07-03 | Invivogen | Pro-cyclic dinucleotide conjugates for cytokine induction |
WO2019129880A1 (en) | 2017-12-29 | 2019-07-04 | Invivogen | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction |
WO2019152661A1 (en) | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11660266B2 (en) | 2018-04-11 | 2023-05-30 | Ohio State Innovation Foundation | Methods and compositions for sustained release microparticles for ocular drug delivery |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
CN108383757A (en) * | 2018-04-12 | 2018-08-10 | 江苏金斯瑞生物科技有限公司 | A kind of preparation method of N ε-tertbutyloxycarbonyl-N α-fluorenylmethyloxycarbonyl-N ε-methyl-lysine |
US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
US12006370B2 (en) | 2018-07-23 | 2024-06-11 | Heidelberg Pharma Research Gmbh | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy |
WO2020206033A1 (en) | 2019-04-02 | 2020-10-08 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
US11484606B2 (en) | 2019-06-07 | 2022-11-01 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2020245283A1 (en) | 2019-06-07 | 2020-12-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2021155028A1 (en) | 2020-01-29 | 2021-08-05 | Kenjockety Biotechnology, Inc. | Anti-mdr1 antibodies and uses thereof |
WO2021247423A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
WO2021247426A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
WO2022043256A1 (en) | 2020-08-23 | 2022-03-03 | Cobiores Nv | Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents |
WO2022051390A1 (en) | 2020-09-02 | 2022-03-10 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
WO2022103603A1 (en) | 2020-11-13 | 2022-05-19 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
WO2022136586A1 (en) | 2020-12-22 | 2022-06-30 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
WO2023194539A1 (en) | 2022-04-07 | 2023-10-12 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
US12121590B2 (en) | 2023-06-06 | 2024-10-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
Also Published As
Publication number | Publication date |
---|---|
AU4599597A (en) | 1998-04-17 |
EP0961619A4 (en) | 2001-09-26 |
CA2264227A1 (en) | 1998-04-02 |
EP0961619A1 (en) | 1999-12-08 |
AU739028B2 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU739028B2 (en) | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells | |
US7816317B2 (en) | Tripeptide prodrug compounds | |
JP3607201B2 (en) | FAP-activated antitumor compound | |
ES2282130T3 (en) | NEW EFFECTS OF DIPEPTIDIL PEPTIDASA IV FOR TOPICAL APPLICATION. | |
AU2002316539C1 (en) | CD10-activated prodrug compounds | |
US6855689B2 (en) | Enzyme-activated anti-tumor prodrug compounds | |
KR100387191B1 (en) | Camptothecin derivatives | |
JP3173786B2 (en) | Thrombin inhibitors and substrates | |
RU2149646C1 (en) | Polymeric conjugate, pharmaceutical composition | |
WO2015106599A1 (en) | Conjugates and compositions for drug delivery | |
EP1753776B1 (en) | Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents | |
KR20090057235A (en) | Lysine-based polymeric linkers | |
WO1998013381A1 (en) | Modified physiologically active proteins and medicinal compositions containing the same | |
JP2005500997A (en) | Trimethyl lock type tetrapartate prodrug | |
US10413614B2 (en) | Conjugates for protection from nephrotoxic active substances | |
JP2011523415A (en) | Novel dual-targeting anti-tumor complex | |
US7064105B2 (en) | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | |
EP1317287A2 (en) | Polymeric conjugates of antitumor agents | |
CA2176414A1 (en) | Acyl guanidine and amidine prodrugs | |
EP0644181B1 (en) | Amino acid derivative and use thereof | |
CN110193086A (en) | A kind of LA-GFLG-DOX conjugate and preparation method thereof and purposes | |
US20070232639A1 (en) | Camptothecin Derivatives Conjugated in Position 20 with Integrin Antagonists | |
CA3171025A1 (en) | Fibroblast activation protein ligands for targeted delivery applications | |
KR20040008135A (en) | Tumour targeting prodrugs activated by metallo matrixproteinases | |
WO1997010262A1 (en) | Peptide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2264227 Country of ref document: CA Ref country code: CA Ref document number: 2264227 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 515981 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997944519 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997944519 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997944519 Country of ref document: EP |